JP2016020378A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016020378A5 JP2016020378A5 JP2015197633A JP2015197633A JP2016020378A5 JP 2016020378 A5 JP2016020378 A5 JP 2016020378A5 JP 2015197633 A JP2015197633 A JP 2015197633A JP 2015197633 A JP2015197633 A JP 2015197633A JP 2016020378 A5 JP2016020378 A5 JP 2016020378A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- norovirus
- group
- gene group
- vlp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 29
- 241001263478 Norovirus Species 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 229920001661 Chitosan Polymers 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims 3
- 230000003232 mucoadhesive effect Effects 0.000 claims 3
- 229920001282 polysaccharide Polymers 0.000 claims 3
- 108090000565 Capsid Proteins Proteins 0.000 claims 2
- 102100023321 Ceruloplasmin Human genes 0.000 claims 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- -1 unurine Polymers 0.000 claims 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims 1
- 239000004382 Amylase Substances 0.000 claims 1
- 102000013142 Amylases Human genes 0.000 claims 1
- 108010065511 Amylases Proteins 0.000 claims 1
- 229920000945 Amylopectin Polymers 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920002567 Chondroitin Polymers 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 229920000045 Dermatan sulfate Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 229920002527 Glycogen Polymers 0.000 claims 1
- 229920002971 Heparan sulfate Polymers 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 229920000288 Keratan sulfate Polymers 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 102000004856 Lectins Human genes 0.000 claims 1
- 108090001090 Lectins Proteins 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 235000019418 amylase Nutrition 0.000 claims 1
- 101150010487 are gene Proteins 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims 1
- 229940051593 dermatan sulfate Drugs 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims 1
- 229940099552 hyaluronan Drugs 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229960000292 pectin Drugs 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000277 virosome Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84791206P | 2006-09-29 | 2006-09-29 | |
| US60/847,912 | 2006-09-29 | ||
| US97339207P | 2007-09-18 | 2007-09-18 | |
| US60/973,392 | 2007-09-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013131559A Division JP5898133B2 (ja) | 2006-09-29 | 2013-06-24 | ノロウイルスワクチン製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016020378A JP2016020378A (ja) | 2016-02-04 |
| JP2016020378A5 true JP2016020378A5 (cg-RX-API-DMAC7.html) | 2016-08-04 |
| JP6134364B2 JP6134364B2 (ja) | 2017-05-24 |
Family
ID=39268804
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530639A Active JP5476544B2 (ja) | 2006-09-29 | 2007-09-28 | ノロウイルスワクチン製剤 |
| JP2013131559A Active JP5898133B2 (ja) | 2006-09-29 | 2013-06-24 | ノロウイルスワクチン製剤 |
| JP2015197633A Active JP6134364B2 (ja) | 2006-09-29 | 2015-10-05 | ノロウイルスワクチン製剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530639A Active JP5476544B2 (ja) | 2006-09-29 | 2007-09-28 | ノロウイルスワクチン製剤 |
| JP2013131559A Active JP5898133B2 (ja) | 2006-09-29 | 2013-06-24 | ノロウイルスワクチン製剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US7955603B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP2601969B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5476544B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101515489B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007303608B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2664157C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1118492T1 (cg-RX-API-DMAC7.html) |
| DK (3) | DK2601969T3 (cg-RX-API-DMAC7.html) |
| ES (3) | ES2577833T3 (cg-RX-API-DMAC7.html) |
| HU (2) | HUE028978T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT2601970T (cg-RX-API-DMAC7.html) |
| PL (2) | PL2601969T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2601970T (cg-RX-API-DMAC7.html) |
| SG (3) | SG174845A1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2601970T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008042789A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007303608B2 (en) * | 2006-09-29 | 2013-05-02 | Takeda Vaccines, Inc. | Norovirus vaccine formulations |
| WO2008113011A2 (en) | 2007-03-14 | 2008-09-18 | Ligocyte Pharmaceuticals, Inc. | Virus like particle purification |
| US10130696B2 (en) | 2007-09-18 | 2018-11-20 | Takeda Vaccines, Inc. | Method of conferring a protective immune response to norovirus |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| SG2013057732A (en) * | 2008-08-08 | 2015-02-27 | Ligocyte Pharmaceuticals Inc | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| US20120121710A1 (en) * | 2009-03-27 | 2012-05-17 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Mucosal Immunization |
| US20110070260A1 (en) * | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
| WO2011079260A2 (en) * | 2009-12-23 | 2011-06-30 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Stabilized virus like particles having enhanced mucosal immunogenicity |
| US8980275B2 (en) | 2010-01-21 | 2015-03-17 | Takeda Vaccines, Inc. | Targeted heterologous antigen presentation on calicivirus virus-like particles |
| AU2012244074B2 (en) * | 2010-04-15 | 2015-01-15 | Km Biologics Co., Ltd. | Methods and compositions for intranasal delivery |
| CA2796593C (en) * | 2010-04-15 | 2020-12-15 | Shin Nippon Biomedical Laboratories, Ltd. | Methods and compositions for intranasal delivery |
| EA202090699A3 (ru) | 2011-07-11 | 2020-11-30 | Такеда Вэксинс, Инк. | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения |
| JOP20130186B1 (ar) * | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
| US20140017257A1 (en) * | 2012-07-11 | 2014-01-16 | Xi Jiang | IgY From Norovirus P Particles And Their Derivatives |
| EP3421997B1 (en) * | 2012-12-28 | 2020-06-17 | Cellestis Limited | A cell mediated immune response assay |
| WO2014145245A2 (en) * | 2013-03-15 | 2014-09-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for norovirus blockade epitopes |
| US9975923B2 (en) | 2013-03-15 | 2018-05-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for norovirus blockade epitopes |
| JP6479305B2 (ja) | 2013-07-12 | 2019-03-06 | 株式会社Ｕｍｎファーマ | ウイルス様粒子の精製方法 |
| JP2015015931A (ja) | 2013-07-12 | 2015-01-29 | 株式会社Ｕｍｎファーマ | ウイルス様粒子を含む培養物の製造方法 |
| JP2015017065A (ja) * | 2013-07-12 | 2015-01-29 | 株式会社Ｕｍｎファーマ | ノロウイルスのウイルス様粒子を含む医薬組成物 |
| JP6356795B2 (ja) | 2013-07-17 | 2018-07-11 | ダウ グローバル テクノロジーズ エルエルシー | メチルセルロースを含む粘膜適用組成物 |
| US10501500B2 (en) | 2013-10-03 | 2019-12-10 | Takeda Vaccines, Inc. | Methods of detection and removal of rhabdoviruses from cell lines |
| WO2015093452A1 (ja) | 2013-12-16 | 2015-06-25 | 武田薬品工業株式会社 | マイクロニードル |
| MX2018002419A (es) | 2015-08-28 | 2018-11-29 | Ology Bioservices Inc | Vacuna de norovirus. |
| KR101914779B1 (ko) * | 2016-03-18 | 2018-11-02 | (주)인테라 | 노로 바이러스 백신을 생산하기 위한 재조합 발현 벡터 |
| CN107184970A (zh) * | 2017-02-16 | 2017-09-22 | 北京生物制品研究所有限责任公司 | 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途 |
| WO2018182983A1 (en) | 2017-03-28 | 2018-10-04 | Children's Hospital Medical Center | Norovirus s particle based vaccines and methods of making and using same |
| PH12020550732A1 (en) | 2017-11-30 | 2021-04-19 | Medicago Inc | Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins |
| EP3752185A1 (en) | 2018-02-15 | 2020-12-23 | Icon Genetics GmbH | Immunogenic composition and vaccine for generating an immune response to norovirus |
| JP6713013B2 (ja) * | 2018-03-06 | 2020-06-24 | 株式会社イーダブルニュートリション・ジャパン | 貝類のノロウイルス不活化方法 |
| EP3821014A4 (en) | 2018-07-13 | 2022-04-20 | Medicago Inc. | Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins |
| EP3840778A1 (en) | 2018-08-20 | 2021-06-30 | Takeda Vaccines, Inc. | Vlp formulations |
| JP2022502482A (ja) * | 2018-09-17 | 2022-01-11 | ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム | 骨損傷を治療するための組成物及び方法 |
| US11523988B2 (en) * | 2018-11-29 | 2022-12-13 | Catalent U.K. Swindon Zydis Limited | Oral dispersible vaccine comprising virosomes |
| EP3698773A1 (en) | 2019-02-21 | 2020-08-26 | Università degli Studi di Parma | Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination |
| CA3133030A1 (en) | 2019-03-12 | 2020-09-17 | Icon Genetics Gmbh | Norovirus-like particles with improved stability |
| WO2021030582A2 (en) * | 2019-08-13 | 2021-02-18 | Altimmune, Inc. | Therapeutic agent effectiveness and its route of administration |
| US20240288407A1 (en) * | 2020-06-15 | 2024-08-29 | CureVac SE | Analysis of nucleic acid mixtures |
| WO2022246323A1 (en) | 2021-05-21 | 2022-11-24 | Takeda Vaccines, Inc. | Solid composition, freeze-drying method and glass vial |
| CN115677838A (zh) * | 2021-07-29 | 2023-02-03 | 成都康华生物制品股份有限公司 | 六价诺如病毒VLPs疫苗及其制备方法 |
| AU2023235760A1 (en) | 2022-03-18 | 2024-10-24 | Denka Company Limited | Virus-like particle containing capsid proteins connected by linker. |
| WO2025076792A1 (en) * | 2023-10-12 | 2025-04-17 | Chengdu Kanghua Biological Product Co., Ltd. | Methods of preparing norovirus vaccine with low amounts of adjuvant |
| CN117330750A (zh) * | 2023-12-01 | 2024-01-02 | 北京生物制品研究所有限责任公司 | 一种筛选新冠病毒早期毒种的方法和制造疫苗的方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6572862B1 (en) | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
| WO1992016543A1 (en) * | 1991-03-25 | 1992-10-01 | Genelabs Incorporated | NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs |
| JPH07509122A (ja) | 1992-04-08 | 1995-10-12 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ レプリゼンテッド バイ ザ セクレター，デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 野生型麻疹ウイルス糖タンパク質：ワクチンおよびその検出方法 |
| ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
| US5788970A (en) | 1994-03-29 | 1998-08-04 | The University Of Maryland College Park | Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon |
| PL183781B1 (pl) | 1994-05-16 | 2002-07-31 | Merck & Co Inc | Sposób wytwarzania szczepionki przeciwko ludzkiemu wirusowi brodawczaków |
| US5645051A (en) | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
| US5861241A (en) | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
| GB9525083D0 (en) | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| US5834015A (en) | 1996-09-11 | 1998-11-10 | Albany Medical College | Protein-lipid vesicles and autogenous vaccine comprising the same |
| US5953727A (en) | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
| US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| KR20010006169A (ko) | 1997-04-08 | 2001-01-26 | 폴락 돈나 엘. | 안정화된 사람 파필로마바이러스 제형물 |
| CA2288129A1 (en) | 1997-05-01 | 1998-11-12 | Chiron Corporation | Use of virus-like particles as adjuvants |
| US20040265377A1 (en) | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
| ATE324436T1 (de) | 1998-08-14 | 2006-05-15 | Merck & Co Inc | Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln. |
| ES2262359T3 (es) | 1998-12-17 | 2006-11-16 | MERCK & CO., INC. | Particulas tipo virus sinteticas con epitores heterologos. |
| ES2313881T3 (es) | 1999-02-05 | 2009-03-16 | MERCK & CO., INC. | Formulaciones de vacunas frente al papilomavirus humano. |
| WO2000079280A1 (en) * | 1999-06-22 | 2000-12-28 | Japan As Represented By Director-General National Institute Of Infectious Diseases | Srsv detection kit |
| WO2003068933A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| US7135180B2 (en) | 2002-04-11 | 2006-11-14 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| CA2486118A1 (en) | 2002-06-07 | 2003-12-18 | Large Scale Biology Corporation | Flexible vaccine assembly and vaccine delivery platform |
| EP1513552B1 (en) | 2002-06-20 | 2010-12-01 | Cytos Biotechnology AG | Packaged virus-like particles in combination with cpg for use as adjuvants with allergens : method of preparation and use |
| JP4675317B2 (ja) | 2003-01-30 | 2011-04-20 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | アジュバント化インフルエンザワクチン |
| WO2004073652A2 (en) | 2003-02-20 | 2004-09-02 | Becton Dickinson And Company | Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| US7879338B2 (en) * | 2003-07-21 | 2011-02-01 | Boyce Thompson Institute For Plant Research | Vectors and methods for immunization against norovirus using transgenic plants |
| EP1670824A2 (en) | 2003-09-24 | 2006-06-21 | Montana State University | Norovirus monoclonal antibodies and peptides |
| WO2005037223A2 (en) | 2003-10-15 | 2005-04-28 | Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
| US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
| US7481997B1 (en) * | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
| US20050260225A1 (en) | 2004-05-18 | 2005-11-24 | Goldberg Joanna B | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
| CU23496A1 (es) | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
| US8029802B2 (en) | 2004-10-20 | 2011-10-04 | Sanofi Pasteur Biologics Co. | Vaccines against Japanese encephalitis virus and West Nile virus |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| CA2593176A1 (en) | 2005-01-05 | 2006-07-13 | Peter D. Katsikis | Delivery vehicles, bioactive substances and viral vaccines |
| US8168771B2 (en) | 2005-01-31 | 2012-05-01 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
| NZ599345A (en) | 2005-02-18 | 2013-07-26 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic Escherichia Coli |
| CN101141979B (zh) | 2005-03-18 | 2013-05-08 | 赛托斯生物技术公司 | 猫变应原融合蛋白及其用途 |
| EP1885394A4 (en) | 2005-06-01 | 2009-10-21 | Dow Global Technologies Inc | PRODUCTION OF MULTIVALENT PARTICLES LIKE VIRUSES |
| EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
| JP5215865B2 (ja) * | 2005-11-22 | 2013-06-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | ノロウイルス抗原およびサポウイルス抗原 |
| JP2007145775A (ja) | 2005-11-29 | 2007-06-14 | Falco Life Science:Kk | ノロウイルスｇｉの高感度検出方法 |
| AU2007303608B2 (en) | 2006-09-29 | 2013-05-02 | Takeda Vaccines, Inc. | Norovirus vaccine formulations |
| SG177141A1 (en) | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| WO2008113011A2 (en) | 2007-03-14 | 2008-09-18 | Ligocyte Pharmaceuticals, Inc. | Virus like particle purification |
| US8474614B2 (en) * | 2007-03-14 | 2013-07-02 | BBY Solutions | Protective container for a flat screen monitor |
| US10130696B2 (en) | 2007-09-18 | 2018-11-20 | Takeda Vaccines, Inc. | Method of conferring a protective immune response to norovirus |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| SG2013057732A (en) | 2008-08-08 | 2015-02-27 | Ligocyte Pharmaceuticals Inc | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| EP2381959A1 (en) | 2009-01-22 | 2011-11-02 | Pharmathene Inc. | Stable vaccine compositions and methods of use |
| AU2010212547B2 (en) | 2009-02-10 | 2015-03-12 | Seqirus UK Limited | Influenza vaccine regimens for pandemic-associated strains |
| US20110070260A1 (en) | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
| US8980275B2 (en) | 2010-01-21 | 2015-03-17 | Takeda Vaccines, Inc. | Targeted heterologous antigen presentation on calicivirus virus-like particles |
| CN105194665A (zh) | 2010-05-26 | 2015-12-30 | 西莱克塔生物科技公司 | 具有不偶合的佐剂的纳米载体组合物 |
| EA202090699A3 (ru) | 2011-07-11 | 2020-11-30 | Такеда Вэксинс, Инк. | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения |
| JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
-
2007
- 2007-09-28 AU AU2007303608A patent/AU2007303608B2/en active Active
- 2007-09-28 SG SG2011071123A patent/SG174845A1/en unknown
- 2007-09-28 ES ES13157572.2T patent/ES2577833T3/es active Active
- 2007-09-28 PT PT131575730T patent/PT2601970T/pt unknown
- 2007-09-28 EP EP13157572.2A patent/EP2601969B1/en active Active
- 2007-09-28 WO PCT/US2007/079929 patent/WO2008042789A1/en not_active Ceased
- 2007-09-28 CA CA2664157A patent/CA2664157C/en active Active
- 2007-09-28 ES ES07853688T patent/ES2420136T3/es active Active
- 2007-09-28 PL PL13157572.2T patent/PL2601969T3/pl unknown
- 2007-09-28 EP EP13173005.3A patent/EP2641613A1/en not_active Withdrawn
- 2007-09-28 EP EP07853688.5A patent/EP2066354B1/en active Active
- 2007-09-28 ES ES13157573.0T patent/ES2618885T3/es active Active
- 2007-09-28 SG SG10201502490YA patent/SG10201502490YA/en unknown
- 2007-09-28 SG SG10202012986SA patent/SG10202012986SA/en unknown
- 2007-09-28 SI SI200731885A patent/SI2601970T1/sl unknown
- 2007-09-28 PL PL13157573T patent/PL2601970T3/pl unknown
- 2007-09-28 HU HUE13157572A patent/HUE028978T2/en unknown
- 2007-09-28 KR KR1020097008725A patent/KR101515489B1/ko active Active
- 2007-09-28 DK DK13157572.2T patent/DK2601969T3/en active
- 2007-09-28 EP EP13157573.0A patent/EP2601970B1/en not_active Revoked
- 2007-09-28 US US12/093,921 patent/US7955603B2/en active Active
- 2007-09-28 HU HUE13157573A patent/HUE032422T2/en unknown
- 2007-09-28 DK DK07853688.5T patent/DK2066354T3/da active
- 2007-09-28 JP JP2009530639A patent/JP5476544B2/ja active Active
- 2007-09-28 DK DK13157573.0T patent/DK2601970T3/en active
- 2007-09-28 LT LTEP13157573.0T patent/LT2601970T/lt unknown
-
2010
- 2010-06-16 US US12/816,495 patent/US8431116B2/en active Active
-
2011
- 2011-12-20 US US13/330,854 patent/US20120093861A1/en not_active Abandoned
-
2013
- 2013-03-15 US US13/837,653 patent/US9308249B2/en active Active
- 2013-03-15 US US13/836,446 patent/US10010599B2/en active Active
- 2013-03-15 US US13/837,885 patent/US9272028B2/en active Active
- 2013-06-24 JP JP2013131559A patent/JP5898133B2/ja active Active
-
2015
- 2015-07-10 US US14/796,714 patent/US9861691B2/en active Active
- 2015-10-05 JP JP2015197633A patent/JP6134364B2/ja active Active
-
2017
- 2017-01-25 CY CY20171100109T patent/CY1118492T1/el unknown
-
2018
- 2018-05-31 US US15/994,887 patent/US10512682B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016020378A5 (cg-RX-API-DMAC7.html) | ||
| JP2014141528A5 (cg-RX-API-DMAC7.html) | ||
| JP2010539192A5 (cg-RX-API-DMAC7.html) | ||
| JP2011530295A5 (cg-RX-API-DMAC7.html) | ||
| Riese et al. | Vaccine adjuvants: key tools for innovative vaccine design | |
| Garcia-Vello et al. | Carbohydrate-based adjuvants | |
| Jabbal-Gill | Nasal vaccine innovation | |
| Slütter et al. | Rational design of nasal vaccines | |
| Yao et al. | Preventative vaccine-loaded mannosylated chitosan nanoparticles intended for nasal mucosal delivery enhance immune responses and potent tumor immunity | |
| ES2568018T3 (es) | Composición de vacuna | |
| EP2720717B1 (en) | Vaccine adjuvant composition comprising inulin particles | |
| EP3308800B1 (en) | Adjuvant for vaccines, vaccine, and immunity induction method | |
| BR112016005966B1 (pt) | Complexo contendo um oligodesoxinucleotídeo e beta-1,3-glucano uso do mesmo, composição farmacêutica, bem como agente para induzir a produção de interferon do tipo i e/ou do tipo ii, e agente imunoestimulante | |
| JP2010163453A5 (cg-RX-API-DMAC7.html) | ||
| Renu et al. | Poly (I: C) augments inactivated influenza virus-chitosan nanovaccine induced cell mediated immune response in pigs vaccinated intranasally | |
| KR20090079912A (ko) | 노로바이러스 백신 제제 | |
| CN102791286A (zh) | 杯状病毒病毒样颗粒上靶定异源抗原的呈递 | |
| JP2017516834A5 (cg-RX-API-DMAC7.html) | ||
| Cevher et al. | Development of chitosan–pullulan composite nanoparticles for nasal delivery of vaccines: in vivo studies | |
| ES2698210T3 (es) | Composiciones que incluyen beta-glucanos y procedimientos de uso | |
| AU2019404430A1 (en) | Norovirus vaccine formulations and methods | |
| Orosco et al. | Navigating the landscape of adjuvants for subunit vaccines: recent advances and future perspectives | |
| Patil et al. | Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration | |
| Masimov et al. | Chitosan non-particulate vaccine delivery systems | |
| CN112294954B (zh) | 一种禽用佐剂组合物及其制备方法和应用 |